Triglav Investments D.O.O. Trims Stock Position in Biogen Inc. $BIIB

Triglav Investments D.O.O. trimmed its position in Biogen Inc. (NASDAQ:BIIB) by 33.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,130 shares of the biotechnology company’s stock after selling 6,000 shares during the quarter. Triglav Investments D.O.O.’s holdings in Biogen were worth $2,135,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Rothschild Investment LLC raised its holdings in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 56 shares during the period. Advisory Services Network LLC raised its holdings in shares of Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 68 shares during the period. Davis Investment Partners LLC raised its holdings in shares of Biogen by 1.7% during the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 71 shares during the period. Optas LLC raised its holdings in shares of Biogen by 4.5% during the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 73 shares during the period. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Biogen by 8.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 89 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Stock Down 0.2%

Shares of Biogen stock opened at $196.00 on Friday. The business’s fifty day moving average price is $186.66 and its two-hundred day moving average price is $182.21. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a market capitalization of $28.94 billion, a P/E ratio of 21.03, a PEG ratio of 1.73 and a beta of 0.19. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the business earned $3.02 EPS. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts forecast that Biogen Inc. will post 14.18 EPS for the current year.

Analysts Set New Price Targets

BIIB has been the topic of several analyst reports. Citigroup raised their target price on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Weiss Ratings upgraded Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Rothschild & Co Redburn raised their price objective on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Evercore initiated coverage on Biogen in a research note on Friday, May 15th. They set an “outperform” rating for the company. Finally, Wall Street Zen upgraded Biogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $215.81.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.